Ferrero S

No ORCID on file · 60 papers in corpus · active 2009-2026

Study types

  • review 22
  • article 21
  • editorial 4
  • letter 4
  • other 3

Condition tags

  • endometriosis 48
  • bowel_endometriosis 6
  • infertility 6
  • dysmenorrhea 4
  • endometrioma 4
  • die_deep_infiltrating 3
  • adenomyosis 3
  • chronic_pelvic_pain 3
  • dyspareunia 2
  • bladder_endometriosis 1
review 2026
The lancet. Gastroenterology & hepatology ·doi:10.1016/S2468-1253(26)00117-2

Bowel involvement is a severe manifestation of deep endometriosis that affects approximately 8-12% of women with endometriosis. Bowel endometriosis is most commonly localised in the rectosigmoid colon and frequently coexists with other pelv…

review 2026
Expert opinion on pharmacotherapy ·doi:10.1080/14656566.2026.2695094

INTRODUCTION: Uterine fibroids and adenomyosis are common estrogen- and progesterone-dependent disorders associated with heavy menstrual bleeding, pelvic pain, anemia, and impaired quality of life. Although surgery remains widely used, ther…

review 2026
Expert opinion on pharmacotherapy ·doi:10.1080/14656566.2026.2685064

INTRODUCTION: Endometriosis is a chronic, estrogen-dependent inflammatory disorder requiring long-term management strategies that balance efficacy with systemic safety. Although hormonal therapies remain the cornerstone of treatment, the op…

review 2026
Expert opinion on drug safety ·doi:10.1080/14740338.2026.2627190

INTRODUCTION: Hormonal therapy is the cornerstone of long-term endometriosis management, especially for women deferring surgery. In patients with comorbid migraine - a common, disabling condition - therapeutic choices must balance efficacy …

2025
Andrology ·doi:10.1111/andr.13811

ObjectiveTo examine the association between semen parameters, assessed according to World Health Organization (WHO)-2021 criteria, and paternal body mass index (BMI) and age, with embryological and clinical outcomes in ICSI cycles involving…

review 2025
Expert opinion on drug safety ·doi:10.1080/14740338.2025.2547017

INTRODUCTION: Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile. AREAS COVERED: This review aims to provide a comprehensive overview of avail…

review 2025
Expert opinion on investigational drugs ·doi:10.1080/13543784.2025.2609734

INTRODUCTION: Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting up to 10% of reproductive-aged women. Current therapies are predominantly hormone-based and offer symptomatic relief without correcting the immune d…

review 2025
Gynecologic and obstetric investigation ·doi:10.1159/000542563

BACKGROUND: Bowel endometriosis is one of the more severe manifestations of deep endometriosis; it may cause pain and intestinal symptoms. The noninvasive diagnosis of bowel endometriosis is of crucial importance in planning the management …

article 2025

Giuseppe Mascellino,1 Antonio Simone Laganà,1 Marco Anatrà,2 Pietro Serra,1 Giada Mesiano,3 Matteo Terrinoni,4,5 Vincenzo Mascellino,6 Simone Ferrero,2 Maurizio Serati,3 Maurizio Leone,2 Fabio Barra2,7 1Unit of Obstetrics and Gynecology, “P…

review 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2024.102528

Ovarian endometriomas (OEs) are commonly detected by ultrasound in individuals affected by endometriosis. Although surgery was widely regarded in the past as the gold standard for treating OEs, especially in the case of large cysts, the sur…

article 2024
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1136/ijgc-2023-005139

OBJECTIVE: To compare survival outcomes and patterns of recurrence between endometriosis-associated ovarian cancer patients and non-endometriosis-associated ovarian cancer patients. METHODS: This retrospective study included data of consec…

editorial 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2024.102504
review 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2023.102454

Endometriosis is a benign, chronic, inflammatory condition affecting up to 10 % of women and characterised by the presence of glands and stroma tissue outside the uterus. Epidemiological and clinical studies demonstrate a consistent associa…

review 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2024.102503

In recent years, advancements in cryopreservation techniques for oocytes, embryos, and ovarian tissue have enabled offering fertility preservation (FP) options to women with endometriosis. It is recommended to always conduct specialized cou…

review 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2024.102493

Deep endometriosis (DE) can be localized in the parametrium, a complex bilateral anatomical structure, sometimes necessitating intricate surgical intervention due to the potential involvement of autonomic nerves, uterine artery, and ureter.…

review 2024
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2024.102496

This narrative review aims to summarize available evidence on the IVF-associated outcomes after surgery for endometriosis. Only one retrospective study investigated if surgical treatment of superficial/peritoneal endometriosis may modify th…

review 2024
Expert opinion on drug safety ·doi:10.1080/14740338.2024.2446424

INTRODUCTION: Endometriosis and pelvic inflammatory disease (PID) are gynecological conditions affecting women of reproductive age and causing pain symptoms. The symptoms caused by these conditions are similar; thus, the differential diagno…

review 2023
Expert opinion on emerging drugs ·doi:10.1080/14728214.2023.2296080

INTRODUCTION: Endometriosis is an estrogen-dependent disease that gives rise to pelvic pain and infertility. Although estroprogestins and progestins currently stand as the first-line treatments for this condition, demonstrating efficacy in …

review 2023
Drugs ·doi:10.1007/s40265-023-01957-7

Adenomyosis, characterized by the growth of endometrial tissue within the uterine wall, poses significant challenges in treatment. The literature primarily focuses on managing abnormal uterine bleeding (AUB) and dysmenorrhea, the main sympt…

editorial 2023
Frontiers in endocrinology ·doi:10.3389/fendo.2023.1334596

EDITORIAL article Front. Endocrinol., 18 December 2023Sec. Reproduction Volume 14 - 2023 | https://doi.org/10.3389/fendo.2023.1334596

review 2023
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2023.102438

As endometriosis is recognized as a contributing factor to infertility, prompting couples to embark on Assisted Reproductive Technology (ART) treatments, it becomes crucial to comprehend the extent and way this condition can affect success …

other 2023
Gynecologic and obstetric investigation ·doi:10.1159/000530461
letter 2023
Journal of reproductive immunology ·doi:10.1016/j.jri.2023.103967

This letter discusses the article "The Effects of Rituximab on Experimental Endometriosis Model in Rats" by Dogan et al., which evaluated the potential therapeutic efficacy of rituximab in an experimental animal model of endometriosis. Whil…

review 2022
Expert opinion on drug metabolism & toxicology ·doi:10.1080/17425255.2022.2113381

INTRODUCTION: Uterine fibroids are the most common benign gynecological tumors affecting women of reproductive ages. Although surgery is the definitive treatment choice, several medical approaches have been investigated to control their sym…

letter 2022
Archives of gynecology and obstetrics ·doi:10.1007/s00404-021-06390-3

Correspondence to the original research entitled "Effects of ranibizumab and zoledronic acid on endometriosis in a rat model" published by Ozdemir et al.